License option agreement with Novartis for target-specific access to TRACER™  next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER

Reader Interactions

Leave A Reply